These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 6250760)

  • 21. Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration.
    Hollister LE; Gillespie HK
    Clin Pharmacol Ther; 1973; 14(3):353-7. PubMed ID: 4698563
    [No Abstract]   [Full Text] [Related]  

  • 22. Tolerance to the effect of delta1-tetrahydrocannabinol on corticosterone levels in mouse plasma produced by repeated administration of cannabis extract or delta1-tetrahydrocannabinol.
    Pertwee RG
    Br J Pharmacol; 1974 Jul; 51(3):391-7. PubMed ID: 4451752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GC/MS and EMIT analyses for delta 9-tetrahydrocannabinol metabolites in plasma and urine of human subjects.
    McBurney LJ; Bobbie BA; Sepp LA
    J Anal Toxicol; 1986; 10(2):56-64. PubMed ID: 3009969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol.
    Lemberger L; Martz R; Rodda B; Forney R; Rowe H
    J Clin Invest; 1973 Oct; 52(10):2411-7. PubMed ID: 4729039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of delta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade.
    Kanakis C; Pouget JM; Rosen KM
    Circulation; 1976 Apr; 53(4):703-7. PubMed ID: 1253395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabinoid concentrations in plasma after passive inhalation of marijuana smoke.
    Mason AP; Perez-Reyes M; McBay AJ; Foltz RL
    J Anal Toxicol; 1983; 7(4):172-4. PubMed ID: 6314043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of physostigmine and delta-9-tetrahydrocannabinol in man.
    Freemon FR; Rosenblatt JE; EL-Yousef MK
    Clin Pharmacol Ther; 1975 Feb; 17(2):121-6. PubMed ID: 1091392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Passive inhalation of marihuana smoke and urinary excretion of cannabinoids.
    Perez-Reyes M; Di Guiseppi S; Mason AP; Davis KH
    Clin Pharmacol Ther; 1983 Jul; 34(1):36-41. PubMed ID: 6305545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats.
    Valiveti S; Agu RU; Hammell DC; Paudel KS; Earles DC; Wermeling DP; Stinchcomb AL
    Eur J Pharm Biopharm; 2007 Feb; 65(2):247-52. PubMed ID: 17014999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Action of delta-9-tetrahydrocannabinol. An approach to the active metabolite hypothesis.
    Hollister LE; Gillespie HK
    Clin Pharmacol Ther; 1975 Dec; 18(6):714-9. PubMed ID: 1204277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Penetration of delta-9-tetrahydrocannabinol and 11-OH-delta-9-tetrahydrocannabinol through the blood-brain barrier.
    Schou J; Prockop LD; Dahlstrom G; Rohde C
    Acta Pharmacol Toxicol (Copenh); 1977 Jul; 41(1):33-8. PubMed ID: 578377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
    Haney M; Malcolm RJ; Babalonis S; Nuzzo PA; Cooper ZD; Bedi G; Gray KM; McRae-Clark A; Lofwall MR; Sparenborg S; Walsh SL
    Neuropsychopharmacology; 2016 Jul; 41(8):1974-82. PubMed ID: 26708108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of effects of marihuana cigarettes to three different potencies.
    Perez-Reyes M; Di Guiseppi S; Davis KH; Schindler VH; Cook CE
    Clin Pharmacol Ther; 1982 May; 31(5):617-24. PubMed ID: 6280918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans.
    Naef M; Russmann S; Petersen-Felix S; Brenneisen R
    J Pharm Sci; 2004 May; 93(5):1176-84. PubMed ID: 15067694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use.
    Odell MS; Frei MY; Gerostamoulos D; Chu M; Lubman DI
    Forensic Sci Int; 2015 Apr; 249():173-80. PubMed ID: 25698515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma concentrations of delta-9-tetrahydrocannabinol and impaired motor function.
    Reeve VC; Grant JD; Robertson W; Gillespie HK; Hollister LE
    Drug Alcohol Depend; 1983 Apr; 11(2):167-75. PubMed ID: 6305619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial.
    Ahmed AI; van den Elsen GA; Colbers A; van der Marck MA; Burger DM; Feuth TB; Rikkert MG; Kramers C
    Eur Neuropsychopharmacol; 2014 Sep; 24(9):1475-82. PubMed ID: 25035121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
    Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
    J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.
    Curran HV; Brignell C; Fletcher S; Middleton P; Henry J
    Psychopharmacology (Berl); 2002 Oct; 164(1):61-70. PubMed ID: 12373420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol.
    Hollister LE; Gillespie H
    Clin Pharmacol Ther; 1975 Jul; 18(1):80-3. PubMed ID: 1097148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.